The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
San Francisco-based surgeon Dr. Anne Peled, a two-time breast most cancers survivor, sat down with CURE to debate present process a sensation-preserving...
Shared decision-making empowers a number of myeloma sufferers and their care companions to actively collaborate with the medical crew on remedy decisions....
Being a a number of myeloma care accomplice entails vital logistical and emotional challenges. Panelists acknowledge the problem in balancing advocacy with...
